CORT (Corcept Therapeutics) Total Operating Expense: $763.9 Mil (TTM As of Mar. 2026)


CORT Corcept Therapeutics Inc CORT
82 GF Score
Price $87.32
GF Value $61.67
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Corcept Therapeutics Total Operating Expense?

Corcept Therapeutics CORT +3.03% 82 Total Operating Expense is $763.9 Mil as of Mar. 2026. GuruFocus rates CORT with a GF Score™ of 82/100 and a GF Value™ of $61.67 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Corcept Therapeutics's Total Operating Expense for the three months ended in Mar. 2026 was $211.6 Mil. Corcept Therapeutics's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $763.9 Mil.

Corcept Therapeutics Total Operating Expense Related Terms

Corcept Therapeutics Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Corcept Therapeutics's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corcept Therapeutics Total Operating Expense Chart

Corcept Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 236.22 283.84 368.61 527.21 703.63

Corcept Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 151.40 164.32 192.82 195.09 211.62
CORT
82GF Score
Corcept Therapeutics Inc CORT
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Corcept Therapeutics Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $763.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of $763.9 Mil mean?
Corcept Therapeutics (CORT) has a Total Operating Expense of $763.9 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Corcept Therapeutics and its competitors.
Is Corcept Therapeutics' Total Operating Expense too high?
Corcept Therapeutics' current Total Operating Expense is $763.9 Mil. Overall, Corcept Therapeutics has a GF Score™ of 82/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Corcept Therapeutics' Total Operating Expense compare to PCVX and IBRX?
Corcept Therapeutics' Total Operating Expense of $763.9 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Corcept Therapeutics and its competitors. Corcept Therapeutics's current Total Operating Expense is $763.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corcept Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Corcept Therapeutics (CORT) is currently considered Significantly Overvalued. The stock's GF Value™ is $61.67, compared to a current price of $87.32 — trading 41.6% above its estimated fair value. The current Total Operating Expense is $763.9 Mil. Corcept Therapeutics' overall GF Score™ is 82/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Corcept Therapeutics (CORT), the current Total Operating Expense is $763.9 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Corcept Therapeutics (CORT) Overvalued in 2026?

Based on GuruFocus' analysis, Corcept Therapeutics stock appears to be overvalued. The current stock price of $87.32 is trading 41.6% above its estimated GF Value™ of $61.67. GuruFocus considers Corcept Therapeutics to be Significantly Overvalued.

Key valuation signals for CORT:

  • Total Operating Expense: $763.9 Mil
  • GF Value™: $61.67 vs. price of $87.32 (41.6% above fair value)
  • GF Score™: 82/100 with 8 warning signs

No single metric tells the full story. See the CORT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Corcept Therapeutics Business Description

Address 101 Redwood Shores Parkway, Redwood City, CA, USA, 94065
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
82GF Score

Get the complete analysis for CORT

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$87.32
Price
$61.67
GF Value